Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.56 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.55 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18294081 | 0.86 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL18294078 | 0.86 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL26209133 | 0.84 | CHRM3 (0.50) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL26729833 | 0.82 | CHRNB4 (0.65) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL8706817 | 0.81 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL8706812 | 0.81 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| Hydrochloric Acid SCHEMBL8706666 | 0.80 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| Hydrochloric Acid SCHEMBL8706659 | 0.80 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNB1 | |
| SCHEMBL32691652 | 0.79 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL26729894 | 0.77 | CHRNB2 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRNB4 282/4885CHRNA3 353/4885CHRNB2 158/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRNB4 282/4885CHRNA3 353/4885CHRNB2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.